[
  {
    "ts": null,
    "headline": "This Rare Disease Biotech Name Teases Around A Buy Point",
    "summary": "Rare disease treatment developer Stoke Therapeutics is Monday's IBD 50 Growth Stocks To Watch pick as the biotech name hit a buy point.  Its shares had climbed sharply despite the broader market sell-off, but the shares lost some of their momentum by the afternoon.  It currently has no products approved by the U.S. Food and Drug Administration, but is focusing on two diseases and has two products in clinical trials.",
    "url": "https://finnhub.io/api/news?id=bbee1328b953210dc7a32d60a8939f2af0f5c2877891134402957430f9ecdc4a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771869551,
      "headline": "This Rare Disease Biotech Name Teases Around A Buy Point",
      "id": 139186642,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BIIB",
      "source": "Yahoo",
      "summary": "Rare disease treatment developer Stoke Therapeutics is Monday's IBD 50 Growth Stocks To Watch pick as the biotech name hit a buy point.  Its shares had climbed sharply despite the broader market sell-off, but the shares lost some of their momentum by the afternoon.  It currently has no products approved by the U.S. Food and Drug Administration, but is focusing on two diseases and has two products in clinical trials.",
      "url": "https://finnhub.io/api/news?id=bbee1328b953210dc7a32d60a8939f2af0f5c2877891134402957430f9ecdc4a"
    }
  }
]